GlassScriptPhysician profile
Michael Roger Thompson
NPI 1023016631
$582.81
in general payments reported to CMS, 2019-2025
13 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.20 · 2020: $11.60 · 2022: $129 · 2023: $179 · 2024: $74.20 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.48 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $137.80 | 2019-2023 | |
| Caris Mpi, INC. | $130.70 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $88.82 | 2022-2023 | Injectafer, Enhertu |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.20 | 2024 | Lifevest |
| Pfizer INC. | $54.78 | 2022-2023 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Seagen INC. | $17.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.35 | 2023 | Ninlaro |
| E.R. Squibb & Sons, L.L.C. | $16.11 | 2023 | Opdivo |
| Cumberland Pharmaceuticals, INC. | $15.00 | 2024 | Sancuso |
| Morphosys, US INC. | $14.61 | 2023 | Monjuvi |
| Exelixis INC. | $11.60 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.